Search Immortality Topics:

Page 11234..1020..»


Category Archives: Human Genetic Engineering

Global CRISPR And CRISPR-Associated (Cas) Genes Market 2020 with COVID-19 After Effects Analysis by Key Players Caribou Biosciences, Addgene, CRISPR…

CRISPR And CRISPR-Associated (Cas) Genes Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The new report on the globalCRISPR And CRISPR-Associated (Cas) Genes marketpublished by theMarket Research Storeincorporates all the essential facts about the CRISPR And CRISPR-Associated (Cas) Genes market. This aids different industry players along with new market entrants to open new gateways for the CRISPR And CRISPR-Associated (Cas) Genes market on a global platform. Through in-depth research and data obtained from the reliable database the qualitative and the quantitative data of the CRISPR And CRISPR-Associated (Cas) Genes market has been updated based on the current market conditions owing toCOVID-19. The overall market conditions have been affected due to the pandemic. The trading conditions and the economy crisis have affected the CRISPR And CRISPR-Associated (Cas) Genes market. The information in the CRISPR And CRISPR-Associated (Cas) Genes market report is updated and precise thus the clients will be able to relate themselves to the current market scenario.

Request Free Sample Copy of CRISPR And CRISPR-Associated (Cas) Genes Market Research Report@http://www.marketresearchstore.com/report/global-crispr-and-crispr-associated-cas-genes-market-608839#RequestSample

The CRISPR And CRISPR-Associated (Cas) Genes market report also encompasses the details about all the market players that are operating in the CRISPR And CRISPR-Associated (Cas) Genes market. The market players includeCaribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon.

The market analysis in the CRISPR And CRISPR-Associated (Cas) Genes market study starts with the market definition and scope. In the next section, there is a brief discussion about the target audience of the market. In the later section, a detailed information about the market growth factors and limitations are discussed along with the market opportunities and challenges that are being faced owing to arise of the pandemic. Research tools and methodologies were used while analyzing the CRISPR And CRISPR-Associated (Cas) Genes market.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-crispr-and-crispr-associated-cas-genes-market-608839

The major section that covers the overall market description is the market segmentation. The CRISPR And CRISPR-Associated (Cas) Genes market includes segments{Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops}; {Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes}. To study any market in detail the major components that need to be analyzed are its product type, application, end-use, the solution and the services that are offered. Details about all these segments helps better understand the market size and demand. Every aspect of every single segment was studied carefully and the impact of COVID-19 was also taken into consideration. Both numerical data and subjective information about every segment is included for better understanding. The regional presence of the CRISPR And CRISPR-Associated (Cas) Genes market is also included. The current market condition in each regions is explained thoroughly as to how the pandemic has affected the CRISPR And CRISPR-Associated (Cas) Genes market demand in a particular region.

Major Advantages for CRISPR And CRISPR-Associated (Cas) Genes Market:

1. Well-organized description of the international CRISPR And CRISPR-Associated (Cas) Genes market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas.2. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the CRISPR And CRISPR-Associated (Cas) Genes industry.3. The CRISPR And CRISPR-Associated (Cas) Genes market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis.4. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global CRISPR And CRISPR-Associated (Cas) Genes market.5. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of CRISPR And CRISPR-Associated (Cas) Genes Report:http://www.marketresearchstore.com/report/global-crispr-and-crispr-associated-cas-genes-market-608839#InquiryForBuying

Here is the original post:
Global CRISPR And CRISPR-Associated (Cas) Genes Market 2020 with COVID-19 After Effects Analysis by Key Players Caribou Biosciences, Addgene, CRISPR...

Posted in Human Genetic Engineering | Comments Off on Global CRISPR And CRISPR-Associated (Cas) Genes Market 2020 with COVID-19 After Effects Analysis by Key Players Caribou Biosciences, Addgene, CRISPR…

Global CRISPR And CRISPR-Associated (Cas) Genes Market with focus on Industry Analysis, Growth Opportunities, Current Trends, Size, Competitive…

The GlobalCRISPR And CRISPR-Associated (Cas) Genes MarketResearch Report is a helpful source of insightful data for business strategists.It provides thedeep insights into the global market revenue, market segments, competitive landscape, manufacturing, and pricing and cost structures, growth factor. The industry overview is added after a widespread study of the significant business drivers, hindering factors and future industry prospect. CRISPR And CRISPR-Associated (Cas) Genes report studies the present state of the market to analyze the future opportunities and risks.

Get FREE Sample Copy (including COVID19 Impact Analysis, FULL TOC, Graphs, and Tables) of this report: https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#request_sample

CRISPR And CRISPR-Associated (Cas) Genes Market Report Scope:

Due to COVID-19 crisis takes over the globe, we are constantly track the changes in the markets, as well as the industry behaviors of the customers worldwide and our estimate about the newest market trends and forecasts are being done after in view of the impact of this pandemic.

Get an Upto 30% Discount On CRISPR And CRISPR-Associated (Cas) Genes Market Report

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation:

By Type:

Genome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

By Application:

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

The Global CRISPR And CRISPR-Associated (Cas) Genes Market report includes the precisely studied and assessed statistics of the key vendor and their scope in the market utilizing several analytical tools. The Porters five forces analysis, SWOT analysis, feasibility study, and investment return breakdown and used to analyze the growth of key vendors in the market. Moreover, the report presents a 360-degree overview of the competitive.

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#inquiry_before_buying

Influence of the CRISPR And CRISPR-Associated (Cas) Genes Market report:

Inquire More about CRISPR And CRISPR-Associated (Cas) Genes MarketReport:

The CRISPR And CRISPR-Associated (Cas) Genes Market Report Addresses the Following Queries:

Table of Contents: CRISPR And CRISPR-Associated (Cas) Genes Market

Chapter 1: Overview of CRISPR And CRISPR-Associated (Cas) Genes Market

Chapter 2:Global Market Status and Forecast by Regions, Type

Chapter 3:Global CRISPR And CRISPR-Associated (Cas) Genes Market Status and Forecast by Downstream Industry

Chapter 5:Market Driving Factor Analysis

Chapter 6:Market Competition Status by Major Key Vendors

Chapter 7:Upstream and Downstream CRISPR And CRISPR-Associated (Cas) Genes Market Analysis

Chapter 8:Cost and Gross Margin Analysis

Chapter 9:Marketing Status Analysis

Chapter 10:CRISPR And CRISPR-Associated (Cas) Genes Market Report Conclusion

For more Information or Browse the complete report @ https://www.globalmarketers.biz/report/life-sciences/global-crispr-and-crispr-associated-(cas)-genes-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131472#table_of_contents

Read the original here:
Global CRISPR And CRISPR-Associated (Cas) Genes Market with focus on Industry Analysis, Growth Opportunities, Current Trends, Size, Competitive...

Posted in Human Genetic Engineering | Comments Off on Global CRISPR And CRISPR-Associated (Cas) Genes Market with focus on Industry Analysis, Growth Opportunities, Current Trends, Size, Competitive…

Joint Study by Sunway University and Harvard Medical School Shows Gene Therapy Can Advance Cancer Treatment – QS WOW News

Sunway Universitys Professor Jeff Tan Kuan Onn of the Department of Biological Sciences and Professor Poh Chit Laa from the Centre for Virus and Vaccine Research, along with their research collaborators from Harvard Medical Schools Center for Stem Cell Therapeutics and Imaging (USA) as well as University of Tennessee Health Science Centre (USA) have completed a study that has demonstrated the efficacy of molecular gene therapy as a new strategy for cancer treatment.

The research could potentially contribute to shorter treatment time for cancers, reduce treatment costs and minimize the adverse effects of current chemo-drugs in cancer patients such as susceptibilities toward microbial infections, hair loss, and other side effects of chemo-drugs that drastically affect the quality of life of cancer patients undergoing therapy.

Principal Investigator Professor Jeff Tan explained, Currently, chemo-drugs are relatively ineffective against cancer cells that have developed drug-resistance resulting in the need for high doses of chemo-drugs or a combination of chemo-drugs to be administered to patients with cancer cells. Chemo-drug resistant cancer cells also can spread quickly and that drastically reduce the survival rate of cancer patients.

Our research utilizes molecular gene therapy which is the introduction of genetic materials into cancer cells to promote the sensitivity of cancer cells to chemo-drugs. By genetically engineering the cancer cells, we find that we can induce the cancer cells to produce activated pro-death and tumor suppressor proteins that cause cell death and growth arrests in cancer cells. The weakened cancer cells can then be killed relatively easily by the administration of chemo-drugs in smaller doses. Ultimately, the research could contribute to increasing the survival rates of cancer patients undergoing cancer treatments he added.

Co-Investigator Professor Poh Chit Laa said that the effectiveness of the strategy has been demonstrated in mice implanted with human breast cancer cells. In the mice that were treated with the gene therapy, the tumors obtained from the treated mice showed significant tumor cell death and the tumors were 20 times smaller and 32 times lighter in volume and weight, respectively, when compared to the tumors obtained from the untreated mice. The results indicated that gene therapy was able to shrink the tumors significantly, even without treatment with chemo-drugs. Small doses of market-available anti-cancer drugs could then be used to kill the cancer cells effectively. We hope to see our research contribute to better survival rates of cancer patients, and minimize the side-effects associated with anti-cancer drugs, said Professor Poh.

We are currently working on investigations to optimize the delivery of the gene therapy and anti-cancer drugs to human tumors with hopes that this will result in tangible clinical outcomes, said Professor Jeff Tan.

The research project was recently published in the peer-review Journal of Cancer Research and Clinical Oncology. Collaborators for the research include Lee Yong Hoi, Pang Siew Wai and Samson Eugin Simon from the Department of Biological Sciences, Sunway University; Esther Revai Lechtich and Khalid Shah, of the Center for Stem Cell Therapeutics and Imaging, Brigham and Womens Hospital, Harvard Medical School (USA); Suriyan Ponnusamy and Ramesh Narayanan from the Department of Medicine, Centre of Cancer Drug Discovery, College of Medicine, University of Tennessee Health Science Centre (USA).

The research is a result of a collaboration agreement between Harvard Medical School and Sunway University aimed at developing new cancer therapies targeting drug-resistant cancer cells. In 2016, Professor Jeff Tan visited Harvard University on the Jeffrey Cheah Travel Grant which enabled him to better understand how cancer research projects are conducted as well as examining experimental models used to study cancer biology at Harvard University, Massachusetts General Hospital (MGH), a hospital affiliated with Harvard Medical School, and the Dana-Farber Cancer Institute.

To read the jointly published article: https://link.springer.com/article/10.1007/s00432-020-03231-9

Read the original post:
Joint Study by Sunway University and Harvard Medical School Shows Gene Therapy Can Advance Cancer Treatment - QS WOW News

Posted in Human Genetic Engineering | Comments Off on Joint Study by Sunway University and Harvard Medical School Shows Gene Therapy Can Advance Cancer Treatment – QS WOW News

This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing – WIRED

Crisprs potential for curing inherited disease has made headlines, including at WIRED, for years. ( Here, here, here, and here.) Finally, at least for one family, the gene-editing technology is turning out to deliver more hope than hype. A year after 34-year-old Victoria Gray received an infusion of billions of Crisprd cells, NPR reported last week that those cells were still alive and alleviating the complications of her sickle cell disease. Researchers say its still too soon to call it a cure. But as the first person with a genetic disorder to be successfully treated with Crispr in the US, its a huge milestone. And with dozens more clinical trials currently in progress, Crispr is just getting started.

Yet for all its DNA-snipping precision, Crispr is best at breaking DNA. In Grays case, the gene editor built by Crispr Therapeutics intentionally crippled a regulatory gene in her bone marrow cells, boosting production of a dormant, fetal form of hemoglobin, and overcoming a mutation that leads to poor production of the adult form of the oxygen-carrying molecule. Its a clever way around Crisprs limitations. But it wont work for a lot of other inherited conditions. If you want to replace a faulty gene with a healthy one, you need a different tool. And if you need to insert a lot of DNA, well, youre kind of out of luck.

Not anymore, says Geoffrey von Maltzahn, the CEO of a new startup called Tessera Therapeutics. The company, founded in 2018 by Boston-based biotech investing powerhouse Flagship Pioneering, where von Maltzahn is a general partner, emerged from stealth on Tuesday with $50 million in initial financing. Tessera has spent the past two years developing a new class of molecular manipulators capable of doing lots of things Crispr can doand some that it cant, including precisely plugging in long stretches of DNA. Its not gene editing, says von Maltzahn. Its gene writing.

Simplistically, we think of it as a new category, says von Maltzahn. Gene writing is able to make either perfect deletions or simple base pair changes, but its wheelhouse is in the full spectrum, and in particular the ability to make large alterations to the genome.

To get beyond simplistics, to understand how gene writing works, you have to take a deep dive into the history of an ancient, invisible battle thats been raging for billions of years.

For nearly as long as there have been bacteria, there have been viruses trying to attack them. These viruses, called phages, are like strings of malicious computer code trying to hack into a bacterial genome to trick it into making more phages. Every day, phages invade and blast apart huge quantities of the worlds bacteria (up to 40 percent of the bacterial population in the oceans alone). To avoid the unrelenting slaughter, bacteria have had to constantly evolve defense systems. Crispr is one of them. Its a way for bacteria to steal a bit of a phages codeits DNA or RNAand store it in a memory bank, like a primordial immune system. Its the longest-running arms race in the history of Earth, says Joe Peters, a microbiologist at Cornell University: That level of evolutionary pressure has driven an incredible amount of novelty in molecular mechanisms for manipulating DNA and RNA.

But bacteria havent just had to contend with foreign viral invaders. Their genomes are also under perpetual assault from within. Through the millennia, as bacteria have been swapping bits of DNA with each other, trying to stay ahead of the next wave of phage attacks, some of those genes evolved the ability to move around and even replicate independently of the rest of their original genome. These so-called mobile genetic elements, or MGEs, carry self-contained code for the machinery to either cut and paste or copy and paste themselves into a new locality, either within their host or into nearby bacteria.

Read the original post:
This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing - WIRED

Posted in Human Genetic Engineering | Comments Off on This Company Wants to Rewrite the Future of Genetic DiseaseWithout Crispr Gene Editing – WIRED

GMOs: Pros and Cons, Backed by Evidence – Healthline

GMOs, short for genetically modified organisms, are subject to a lot of controversy.

According to the U.S. Department of Agriculture (USDA), GMO seeds are used to plant over 90% of all maize (corn), cotton, and soy grown in the United States, which means that many of the foods you eat likely contain GMOs (1).

Although most notable organizations and research suggest that GMO foods are safe and sustainable, some people claim they may harm your health and the environment.

This article helps explain what GMOs are, provides a balanced explanation of their pros and cons, and gives guidance on how to identify GMO foods.

GMO, which stands for genetically modified organism, refers to any organism whose DNA has been modified using genetic engineering technology.

In the food industry, GMO crops have had genes added to them for various reasons, such as improving their growth, nutritional content, sustainability, pest resistance, and ease of farming (2).

While its possible to naturally give foods desirable traits through selective breeding, this process takes many generations. Also, breeders may struggle to determine which genetic change has led to a new trait.

Genetic modification significantly accelerates this process by using scientific techniques that give the plant the specific desired trait.

For example, one of the most common GMO crops is Bt corn, which is genetically modified to produce the insecticide Bt toxin. By making this toxin, the corn is able to resist pests, reducing the need for pesticides (3).

GMO crops are incredibly common in the United States, with at least 90% of soy, cotton, and corn being grown through genetic techniques (4).

In fact, its estimated that up to 80% of foods in supermarkets contain ingredients that come from genetically modified crops.

While GMO crops make farming much easier, there is some concern around their potential effect on the environment and their safety for human consumption specifically surrounding illnesses and allergies (5).

However, the Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and USDA maintain that GMOs are safe for human and animal consumption (6).

GMOs are food items that have been made using genetic engineering techniques. They comprise 90% of soy, cotton, and corn grown in the United States and are deemed safe for human consumption.

GMO foods may offer several advantages to the grower and consumer.

For starters, many GMO crops have been genetically modified to express a gene that protects them against pests and insects.

For example, the Bt gene is commonly genetically engineered into crops like corn, cotton, and soybeans. It comes from a naturally occurring bacteria known as Bacillus thuringiensis.

This gene produces a protein that is toxic to several pests and insects, which gives the GMO plants a natural resistance. As such, the GMO crops dont need to be exposed to harmful pesticides as often (7).

In fact, an analysis of 147 studies from 2014 found that GMO technology has reduced chemical pesticide use by 37% and increased crop yields by 22% (8).

Other GMO crops have been modified with genes that help them survive stressful conditions, such as droughts, and resist diseases like blights, resulting in a higher yield for farmers (9, 10, 11).

Together, these factors help lower the costs for the farmers and consumers because it allows a greater crop yield and growth through harsher conditions.

Additionally, genetic modification can increase the nutritional value of foods. For example, rice high in beta carotene, also called golden rice, was developed to help prevent blindness in regions where local diets are chronically deficient in vitamin A (12).

Moreover, genetic modification may be used simply to enhance the flavor and appearance of foods, such as the non-browning apple (13).

In addition, current research suggests that GMO foods are safe for consumption (14).

GMO foods are easier and less costly for farmers to grow, which makes them cheaper for the consumer. GMO techniques may also enhance foods nutrients, flavor, and appearance.

Although current research suggests that GMO foods are safe, there is some concern around their long-term safety and environmental impact (14).

Here are some of the key concerns around GMO consumption.

There is some concern that GMO foods may trigger an allergic reaction.

This is because GMO foods contain foreign genes, so some people worry that they harbor genes from foods that may prompt an allergic reaction.

A study from the mid-1990s found that adding a protein from Brazil nuts to GMO soybeans could trigger an allergic reaction in people sensitive to Brazil nuts. However, after scientists discovered this, they quickly abandoned this GMO food (15).

Although allergy concerns are valid, there have been no reports of allergic reactions to GMO foods currently on the market.

According to the FDA, researchers who develop GMO foods run tests to ensure that allergens arent transferred from one food to another (16).

In addition, research has shown that GMO foods are no likelier to trigger allergies than their non-GMO counterparts (17).

Yet, if you have a soy allergy, both GMO and non-GMO soy products will prompt an allergic reaction.

Similarly, theres a common concern that GMO foods may aid the progression of cancers.

Because cancers are caused by DNA mutations, some people fear that eating foods with added genes may affect your DNA.

This worry may stem partly from an early mice study, which linked GMO intake to a higher risk of tumors and early death. However, this study was later retracted because it was poorly designed (18, 19, 20).

Currently, no human research ties GMO intake to cancers.

The American Cancer Society (ACS) has stated that theres no evidence to link GMO food intake to an increased or decreased risk of cancer (21).

All the same, no long-term human studies exist. Thus, more long-term human research is needed.

Although GMO crops are convenient for farmers, there are environmental concerns.

Most GMO crops are resistant to herbicides, such as Roundup. This means that farmers can use Roundup without fear of it harming their own crops.

However, a growing number of weeds have developed resistance to this herbicide over time. This has led to even more Roundup being sprayed on crops to kill the resistant weeds because they can affect the crop harvest (22, 23, 24).

Roundup and its active ingredient glyphosate are subject to controversy because animal and test-tube studies have linked them to various diseases (25, 26, 27).

Still, a review of multiple studies concluded that the low amounts of glyphosate present on GMO foods are safe for human consumption (28).

GMO crops also allow for fewer pesticide applications, which is a positive for the environment.

That said, more long-term human research is necessary.

The main concerns around GMOs involve allergies, cancer, and environmental issues all of which may affect the consumer. While current research suggests few risks, more long-term research is needed.

Although GMO foods appear safe for consumption, some people wish to avoid them. Still, this is difficult since most foods in your supermarket are made with ingredients from GMO crops.

GMO crops grown and sold in the United States include corn, soybean, canola, sugar beet, alfalfa, cotton, potatoes, papaya, summer squash, and a few apple varieties (29).

In the United States, no regulations currently mandate the labeling of GMO foods.

Yet, as of January 2022, the USDA will require food manufacturers to label all foods containing GMO ingredients (6).

That said, the labels wont say GMO but instead the term bioengineered food. It will display either as the USDA bioengineered food symbol, listed on or near the ingredients, or as a scannable code on the package with directions, such as Scan here for more information (6).

Presently, some foods may have a third-party Non-GMO project verified label, which indicates that the product contains no GMOs. However, this label is voluntary.

Its also worth noting that any food labeled 100% organic does not contain any GMO ingredients, because U.S. law prohibits this. However, if a product is simply labeled organic, it may contain some GMOs (30).

In the European Union (EU), foods with more than 0.9% GMO ingredients must list genetically modified or produced from genetically modified [name of food]. For foods without packaging, these words must be listed near the item, such as on the supermarket shelf (31).

Until the new regulations come into place in the United States, there is no clear way to tell if a food contains GMO ingredients.

However, you can try to avoid GMO foods by eating locally, as many small farms are unlikely to use GMO seeds. Alternatively, you can avoid foods that contain ingredients from the GMO crops listed above.

Until the 2022 USDA rule takes effect, its hard to determine which foods contain GMOs in the United States. You can avoid GMOs by limiting GMO ingredients, eating locally, looking for third-party non-GMO labels, or buying 100% organic.

GMOs are foods that have been modified using genetic techniques.

Most foods in your local supermarket contain GMO ingredients because theyre easier and more cost-effective for farmers, which makes them cheaper for the consumer.

In the United States, foods grown using GMO techniques include corn, soybean, canola, sugar beet, alfalfa, cotton, potatoes, papaya, summer squash, and a few varieties of apples.

Although current research suggests that GMO foods are safe for consumption, some people are concerned about their potential health effects. Due to a lack of long-term human studies, more research is needed.

In the United States, its currently not mandatory to label foods that contain GMOs. However, as of 2022, all foods that contain GMO ingredients must have the term bioengineered food somewhere on the packaging or a scannable code to show that it has GMO ingredients.

Here is the original post:
GMOs: Pros and Cons, Backed by Evidence - Healthline

Posted in Human Genetic Engineering | Comments Off on GMOs: Pros and Cons, Backed by Evidence – Healthline

Perspective on Pharma: Moving from academia to industry – EPM Magazine

In this Perspective on Pharma feature, Jung Doh, market development scientist at Beckman Coulter Life Sciences, explains how they entered the pharmaceutical industry after an unexpected opportunity arose.

As an early career scientist with a good number of years of graduate and post-doctoral training (two post-docs, actually), I made an unexpected leap: from academiawhere I thought I would spend my entire professional lifeto industry. And though it wasnt a move Id initially planned, Im the first to say that Im incredibly happy to have ended up here, since its afforded me research and personal growth opportunities I didnt even know I wanted.

After I received my doctorate in biology, I completed a post-doc in HIV research and a second, NASA-funded post-doc in the effects of microgravity on genomes. My dreamand a very concrete goal for many yearswas to become a professor at a research university, running my own lab in an area I was passionate about.

But then life intervened: my wife was offered a teaching position in Indianapolis that she couldnt pass up, so we relocated. After a few months of fruitless application to teaching and research positions at local universities, I started looking elsewhere. There are a lot of pharma and biotech companies in Indianapolis, so I started exploring some of them. In the interview process, (and much to my surprise), I discovered that they shared many of the same passions and goals I did: to benefit human health and life in fundamental and lasting ways.

The company where I ended up and still work, Beckman Coulter Life Sciences, was particularly interesting to me, since one of their key focuses was on next generation sequencing (NGS). Toward the end of my Ph.D. and in my post-doc training, NGS was becoming more routine, and I was fortunate to be able to learn and apply the techniques in my own research.

So I joined Beckman Coulter Life Sciences, which offers a range of scientific research instruments used to study complex biological problems and to advance scientific breakthroughs, first as a marketing application scientist, and then expanding into a dual role as application scientist and proof of principle scientist. In the latter, I worked with customers to develop modified protocols and tools to help research be done more efficiently. I then became product manager for our genomics product line, and as of this year, I have yet another new role, as market development scientist. In this role, I engage with the scientific community to learn from them, as well as support them to perform research better, faster, and with superior results and outcomes. I also bring the learnings and techniques gained from these collaborations to create collateral to offer other labs, or help our internal team develop product offerings for a specific need.

After making the leap into industry, I never looked back. There are, of course, benefits to both sectors. In academia, theres a certain degree of freedom and job securityonce youre tenured, that is. But it takes a lot to get tenured these daysthe funding and grants and a constant stream of publicationsparticularly in biology and related disciplines.

Though industry may seem more constrained at first glance, in many ways, theres as much or more opportunity, since there are a plethora of techniques to learn and apply in novel ways. And since technology evolves so rapidly, especially in genetic engineering and diagnostics, it seems like there are always new methods to master.

Related to this aspect, and alluded to earlier, is the strong sense that my and my colleagues work is genuinely translating into helping people across the globe. I got an inkling of that in the interview process, but its also been a palpable part of my work here. With the current pandemic, for instance, the company came together, and, within a matter of weeks, we were able to offer labs RNA extraction solutions for the virus, which are so critical right now. I felt honoured to be part of a company doing such great work, with flexibility and speed. It definitely speaks to the versatility of the industry.

Beyond the scientific, Ive learned about areas seemingly outside of science, but that are actually integral parts of the business. When I was product manager, for instance, I learned how to manage people, run meetings, build financial models, approach marketing and sales, and many other facets of the business. I had no formal business training going in, but you learn by doing, from your manager and peers. I ended up really loving all these other parts of the business of sciencetheyre challenging, but incredibly rewarding, because they push you beyond your comfort zone into uncharted areas. For that, industry has opened up areas that I didnt even know would be important, let alone fun and rewarding.

Finally, Ive been surprised and heartened by the strong sense of family that exists within a company. Part of this is felt through the opportunities for development, which is evident in all the stages I went through and all the roles Ive had. Theres a sense that staff are supported to grow as scientists and as people, which has made my accidental leap into industry all the more fulfilling.

For young scientists, theres a lot to think about when making decisions about what to study and what track to follow. I would encourage people to not get too hung up on tracks, but to stay open to the possibilitiesin other words, dont get too stuck on academia as the only option just because its where youve done your training. What really matters is having a passion for what you do, and following your interests. Genetic engineering is an area thats exploded in recent years, and will likely grow in the coming years. Ive been lucky that my own work has translated so tangibly into helping people, and at a large scalebut the same is true for many other areas in medical science. So carry onyou may end up in a totally different place from where you started, and thats not a bad thing at all.

More:
Perspective on Pharma: Moving from academia to industry - EPM Magazine

Posted in Human Genetic Engineering | Comments Off on Perspective on Pharma: Moving from academia to industry – EPM Magazine